Hytera Group Harvests Five Prestigious ICCA Awards for Innovations and Market Excellence
5.7.2022 16:29:00 EEST | Business Wire | Press release
Hytera, a leading global provider of professional communications technologies and solutions, together with its subsidiaries Sepura and Teltronic, won awards in 5 categories at the International Critical Communications Awards (ICCAs) 2022 held in Vienna, Austria. The ICCAs, presented by The Critical Communications Association (TCCA), are the most prestigious awards in critical communications celebrating the very best of the sector across a variety of verticals and recognizing those who have made significant and individual contributions to the critical communications industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220705005515/en/
Hytera Group Wins Five ICCA Awards in Critical Communications (Graphic: Business Wire)
Hytera was firstly awarded “Best Use of Critical Communications in Transport” for a Sri Lanka Railway (SLR) Telecommunications Project. This project enabled Hytera’s 3GPP-compliant MCS Solution to interconnect the SLR sites and provide railway personnel with real-time access to critical data. This allowed them to better serve passengers and provide a smooth and safe operation for train drivers by improving punctuality and reducing railway accidents.
Sepura also claimed an ICCA award for “Best Use of Critical Communications in Mining, Oil & Gas” for the AutoMate App SPACE Application and SCG22 Mobile Radio which was part of the National Wireless Mining Solution. The solution contributed to the operational performance and safety of staff by enabling radio automation through geo-fencing and situational triggers in iron ore mines in Australia.
The SCU3, Sepura’s latest broadband vehicle device, won “Best MX-C Device of the Year”. This technology aroused considerable interests amongst professional communication users looking for future-proof, powerful data capability to enhance their communications solutions.
Sepura’s Senior Specialist Diana Ball was recognized for her “Outstanding Contribution to Critical Communications” for the development of TETRA standards that are still trusted by users to ensure interoperability between suppliers.
Teltronic’s EDESUR project was next awarded “Best Use of Critical Communications in Utilities”. The NEBULA TETRA infrastructure allowed a private electricity distribution company in Argentina to realize the real-time monitoring and fault detection of a power distribution network, and further improve company management and operational efficiency thanks to Teltronic’s unique SDM (Synchronous Data Management) technology.
In addition to securing these awards, Hytera Group was also shortlisted for a number of additional categories including:
Best MC-X Device of the Year
Hytera PDM680 Rugged MCS Radio
Teltronic RTP-800, the First MCX Cab Radio for Transport
Best MC-X solutions of the year
Sepura SCU3 Broadband Vehicle Device
Best TETRA Device of the Year
Hytera PTC680 Multi-mode Radio
Sepura SCG22 Mobile TETRA Radio
Best Use of Advanced Technology
Hytera AI-based Noise Cancellation for Two-way Radios
Best Use of Critical Communications in Public Safety
Teltronic: RESCAN, Reliability and Maximum Coordination in the Fight against the Volcano
Best Use of Critical Communications in Transport
Hytera: Kazakhstan Railway Runs Safely and Efficiently with TETRA Communications System
Emerging Technology, Product or Solutions
Hytera PNC560, World’s First 5G MCPTT Device
Recently Hytera has released a number of innovations from its wide range of product lines, including the latest H-Series DMR Radios, Body-worn Cameras, PTToC Radios & MCS Radios, Multi-mode Rugged Radio and 5G Xsecure Rugged Device. Also the newly launched Hytera Convergence-Native Solutions (including HyTalk, HyTalk Pro and HyTalk MC), composed of different modules, integrates existing network infrastructures, unifies the network core and the communication platform, and provides open API for new service deployment.
With cutting-edge critical communication technologies, Hytera will continue to bring value to global customers leveraging its technologies and professionals.
For more information about Hytera at ICCAs 2022, please visit: https://www.hytera.com/en/media-center/event/hytera-group-won-international-critical-communication-awards.html
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220705005515/en/
Contact information
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom